Tuck conference explores pharmaceutical industry's dramatically changing business model
FOR IMMEDIATE RELEASE—February 20, 2009
CONTACT: Kim Keating, 603-646-2733
HANOVER, N.H.—With a major overhaul of the U.S. healthcare system ranking among the highest priorities of the new Obama administration, the third annual Tuck Global Healthcare Conference will focus on dramatically new approaches pharmaceutical companies are exploring to reduce drug costs and add value to their products and services. The key topics of discussion at the conference on February 27 will be the outsourcing of costly activities such as research and development, clinical trials, and manufacturing, as well as innovations aimed at physicians, patients, and insurers that help better assure the effectiveness of drug treatments.
Presented by the Tuck Healthcare Club and the Center for International Business at the Tuck School of Business at Dartmouth, the conference is open to Tuck students, Dartmouth undergraduates, and Dartmouth Medical School students, as well as medical professionals, academics and industry participants.
Steven Burrill, CEO of Burill & Company, will deliver the keynote address "Navigating the Sea Change." Burill will contend that though the current global financial crisis will be less devastating for the life sciences industry than for other industries, it nevertheless will profoundly reshape the business.
Following the keynote address, two expert panels will convene. The first panel, "Offshoring and outsourcing: responding to a changing global economy," will be moderated by Adimab Vice President of Finance and Operations Errik Anderson T'07. Joining him to discuss the nature, benefits, and risks of offshoring and outsourcing parts of the pharmaceutical production process will be Wuxi Pharma Business Development Vice President Steven Hutchins, Sepracor Senior Brand Manager Julia Dan-Tu T'05, and Pfizer former R&D Director Preston Hensley.
BCG Partner and Managing Director Zhenya Lindgardt will moderate the second panel, "New value propositions: which innovation will win?" Joining her in exploring various proposed innovations by pharmaceutical companies will be J&J Senior Director of Internal Ventures Brian Meltzer, Novartis Evidence-Based Medicine Vice President Joanne Chang, Burrill & Company Director Michael Keyoung, and the National Comprehensive Cancer Network's CEO William McGivney.
BCG Partner and Managing Director Martin Reeves will deliver the conference's closing address.
Conference sponsors include Tuck's Center for International Business, Biogen Idec, sanofi aventis, the John Sloan Dickey Center for International Understanding at Dartmouth College, Boston Scientific, Bristol-Meyers Squibb, Genentech, and the Boston Consulting Group.
The Center for International Business at Tuck is dedicated to research, education, and dialogue on international issues facing business and national leaders. For more details about the event, visit the center's website.
Founded in 1900, Tuck is the first graduate school of management in the country and consistently ranks among the top business schools worldwide. Tuck remains distinctive among the world's great business schools by combining human scale with global reach, rigorous coursework with experiences requiring teamwork, and valued traditions with innovation.
|
